Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

James Bowman

Orthopaedic Surgery Birmingham, AL Medical Doctor

NPI 1003105719 CMS profile 1390986

2700 10Th Ave S Ste 200, Birmingham, AL 35205

Open in the dashboard

General payments

$6,213

100 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, James Bowman of Birmingham, AL is reported in the CMS Open Payments database as having received $6,213 across 100 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 61st percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,451 26
2024 General $510 10
2023 General $1,397 13
2022 General $576 16
2021 General $491 16
2020 General $16 1
2019 General $772 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Bowman
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to James Bowman were reported at $2,451. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year James Bowman Orthopaedic Surgery median Middle half National median
2019 $772 $644 $140–$2,844 $163
2020 $16 $312 $75–$1,860 $114
2021 $491 $520 $117–$2,495 $132
2022 $576 $598 $128–$2,731 $149
2023 $1,397 $461 $128–$2,264 $160
2024 $510 $497 $134–$2,475 $164
2025 $2,451 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $1,985 16 payments
  2. Zimmer Biomet Holdings, Inc. $1,312 13 payments
  3. DePuy Synthes Sales Inc. $474 10 payments
  4. Orthalign Inc $202 2 payments
  5. Innovation Technologies Inc $189 2 payments
  6. Pacira Pharmaceuticals Incorporated $167 8 payments
  7. Osteoremedies, LLC $166 1 payment
  8. Smith+Nephew, Inc. $150 2 payments
  9. LinkBio Corp $145 1 payment
  10. Nevro Corp. $143 1 payment
  11. Other $1,280 44 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,657 94 payments
  2. Travel and Lodging $1,556 6 payments
Products named General payments · program years 2019–2025
  1. Oxford $1,039 7 payments
  2. MAKO Knees, Hips $982 4 payments
  3. MAKO Knees, Hips $503 8 payments
  4. PANGEA $333 2 payments
  5. AXSOS Locking Plates $311 2 payments
  6. AXSOS Non-Locking Plate $311 2 payments
  7. ORTHALIGN PLUS $202 2 payments
  8. SYMPHONY $190 2 payments
  9. Irrisept $189 2 payments
  10. XPERIENCE $166 1 payment
  11. Other $4,114 105 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

676

Median for Orthopedic Surgery: 203

Drug cost

$4,868

Median for Orthopedic Surgery: $1,433

Branded share of claims

3.6%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Methocarbamol Generic 122 $1,103
Oxycodone Hcl Generic 156 $1,100
Celecoxib Generic 29 $712
Methylprednisolone Generic 45 $396
Clindamycin Hcl Generic 31 $345
Meloxicam Generic 55 $237
Tramadol Hcl Generic 74 $210
Cefadroxil Generic 20 $207
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 24 $186
Cephalexin Generic 17 $145

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 57 billing codes

Paid by Medicare

$158,978

Of which drugs: $29,183

Medicare patients

291

Average age 75

Services billed

3,867

175 women, 116 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 32%
Depression 32%
Diabetes 27%
Chronic kidney disease 27%
COPD 19%
Atrial fibrillation 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg J3304 Office 20 1,472 $20,177
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 81 443 $2,312

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Zilretta
  • Pacira Pharmaceuticals Incorporated $17
$17 — 1,472
Exparel
  • Pacira Pharmaceuticals Incorporated $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

100 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record